SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (1924)9/30/1997 12:00:00 PM
From: Joe E.   of 6136
 
Henry:
Re your "I didn't quote anything..."
Sorry to apparently imply that you did something other than upload the article. In my mind quoting and uploading seemed equivalent, but I can see how you could see a difference. Sorry.

There have been some reports of studies of the cross resistance in vitro, and IMO they indicate that the mutations that lead to resistance to Viracept are sometimes the same as but often different from the viral mutations that lead to resistance to the other protease inhibitors. It does appear that the cross resistance problem is less with Viracept than the others. It would have been great if there was no cross resistance, but apparently there is some.

Also, thanks for your advice about the press.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News